RNAi medicine for the brain: Progresses and challenges

Human Molecular Genetics

Volumn 20, Issue , 2011, Pages

  Boudreau, Ryan L ^a   Rodríguez Lebrón, Edgardo ^a   Davidson, Beverly L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; EXPORTIN 5; LIPOSOME; MESSENGER RNA; MICRORNA; POLYGLUTAMINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ALZHEIMER DISEASE; ARTICLE; BRAIN DEGENERATION; CELL FATE; CENTRAL NERVOUS SYSTEM DISEASE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DRUG HALF LIFE; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUNTINGTON CHOREA; INNATE IMMUNITY; KENNEDY DISEASE; LENTIVIRINAE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RNA INTERFERENCE; RNA TRANSCRIPTION; RNA TRANSLATION; SPINOCEREBELLAR DEGENERATION; VIRAL GENE DELIVERY SYSTEM;

BRAIN; CENTRAL NERVOUS SYSTEM; GENE SILENCING; GENE THERAPY; HUMANS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; PEPTIDES; RNA INTERFERENCE;

EID: 79956028473     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr137     Document Type: Article

References (88)

1. Fire, A., Xu, S.Q., Montgomery, M.K., Kostas, S.A., Driver, S.E. and Mello, C.C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391, 806-811.
2. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. and Tuschl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
3. McCaffrey, A.P., Meuse, L., Pham, T.T., Conklin, D.S., Hannon, G.J. and Kay, M.A. (2002) RNA interference in adult mice. Nature, 418, 38-39.
4. Xia, H., Mao, Q., Paulson, H.L. and Davidson, B.L. (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol., 20, 1006-1010.
5. Davis, M.E., Zuckerman, J.E., Choi, C.H., Seligson, D., Tolcher, A., Alabi, C.A., Yen, Y., Heidel, J.D. and Ribas, A. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 464, 1067-1070.
6. Carrington, J.C. and Ambros, V. (2003) Role of microRNAs in plant and animal development. Science, 301, 336-338.
7. Krol, J., Loedige, I. and Filipowicz, W. (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet., 11, 597-610.
8. Lee, Y., Jeon, K., Lee, J.T., Kim, S. and Kim, V.N. (2002) MicroRNA maturation: stepwise processing and subcellular localization. EMBO J., 21, 4663-4670.
9. Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Radmark, O., Kim, S. et al. (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature, 425, 415-419.
10. Gregory, R.I., Yan, K.P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N. and Shiekhattar, R. (2004) The Microprocessor complex mediates the genesis of microRNAs. Nature, 432, 235-240.
11. Yi, R., Qin, Y., Macara, I.G. and Cullen, B.R. (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev., 17, 3011-3016.
12. Provost, P., Dishart, D., Doucet, J., Frendewey, D., Samuelsson, B. and Radmark, O. (2002) Ribonuclease activity and RNA binding of recombinant human Dicer. EMBO J., 21, 5864-5874.
13. Schwarz, D.S., Hutvagner, G., Du, T., Xu, Z., Aronin, N. and Zamore, P.D. (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell, 115, 199-208.
14. Khvorova, A., Reynolds, A. and Jayasena, S.D. (2003) Functional siRNAs and miRNAs exhibit strand bias. Cell, 115, 209-216.
15. Lewis, B.P., Burge, C.B. and Bartel, D.P. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120, 15-20.
16. Matveeva, O., Nechipurenko, Y., Rossi, L., Moore, B., Saetrom, P., Ogurtsov, A.Y., Atkins, J.F. and Shabalina, S.A. (2007) Comparison of approaches for rational siRNA design leading to a new efficient and transparent method. Nucleic Acids Res., 35, e63.
17. Matranga, C., Tomari, Y., Shin, C., Bartel, D.P. and Zamore, P.D. (2005) Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell, 123, 607-620.
18. Leuschner, P.J., Ameres, S.L., Kueng, S. and Martinez, J. (2006) Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep., 7, 314-320.
19. Birmingham, A., Anderson, E., Sullivan, K., Reynolds, A., Boese, Q., Leake, D., Karpilow, J. and Khvorova, A. (2007) A protocol for designing siRNAs with high functionality and specificity. Nat. Protoc., 2, 2068-2078.
20. Jackson, A.L. and Linsley, P.S. (2010) Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov., 9, 57-67.
21. Behlke, M.A. (2008) Chemical modification of siRNAs for in vivo use. Oligonucleotides, 18, 305-319.
22. Paul, C.P., Good, P.D., Winer, I. and Engelke, D.R. (2002) Effective expression of small interfering RNA in human cells. Nat. Biotechnol., 20, 505-508.
23. Zeng, Y., Wagner, E.J. and Cullen, B.R. (2002) Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell, 9, 1327-1333.
24. Boudreau, R.L., Mas Monteys, A. and Davidson, B.L. (2008) Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA, 14, 1834-1844.
25. Wolff, J.A. and Budker, V. (2005) The mechanism of naked DNA uptake and expression. Adv. Genet., 54, 3-20.
26. Rubinson, D.A., Dillon, C.P., Kwiatkowski, A.V., Sievers, C., Yang, L., Kopinja, J., Rooney, D.L., Ihrig, M.M., McManus, M.T., Gertler, F.B. et al. (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet., 33, 401-406.
27. Davidson, B.L. and Harper, S.Q. (2005) Viral delivery of recombinant short hairpin RNAs. Methods Enzymol., 392, 145-173.
28. Davidson, B.L. and Breakefield, X.O. (2003) Viral vectors for gene delivery to the nervous system. Nat. Rev. Neurosci., 4, 353-364.
29. Heilbronn, R. and Weger, S. (2010) Viral vectors for gene transfer: current status of gene therapeutics. Handb. Exp. Pharmacol., 197, 143-170.
30. Grimm, D., Streetz, K.L., Jopling, C.L., Storm, T.A., Pandey, K., Davis, C.R., Marion, P., Salazar, F. and Kay, M.A. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 441, 537-541.
31. Castanotto, D., Sakurai, K., Lingeman, R., Li, H., Shively, L., Aagaard, L., Soifer, H., Gatignol, A., Riggs, A. and Rossi, J.J. (2007) Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res., 35, 5154-5164.
32. Boudreau, R.L., Martins, I. and Davidson, B.L. (2009) Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol. Ther., 17, 169-175.
33. Jackson, A.L., Bartz, S.R., Schelter, J., Kobayashi, S.V., Burchard, J., Mao, M., Li, B., Cavet, G. and Linsley, P.S. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol., 21, 635-637.
34. Birmingham, A., Anderson, E.M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., Maksimova, E., Robinson, K., Karpilow, J. et al. (2006) 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods, 3, 199-204.
35. McBride, J.L., Boudreau, R.L., Harper, S.Q., Staber, P.D., Monteys, A.M., Martins, I., Gilmore, B.L., Burstein, H., Peluso, R.W., Polisky, B. et al. (2008) Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl Acad. Sci. USA, 105, 5868-5873.
36. Aguzzi, A. and O'Connor, T. (2010) Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov., 9, 237-248.
37. Bertram, L., Lill, C.M. and Tanzi, R.E. (2010) The genetics of Alzheimer disease: back to the future. Neuron, 68, 270-281.
38. Singer, O., Marr, R.A., Rockenstein, E., Crews, L., Coufal, N.G., Gage, F.H., Verma, I.M. and Masliah, E. (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci., 8, 1343-1349.
39. Rodriguez-Lebron, E., Gouvion, C.M., Moore, S.A., Davidson, B.L. and Paulson, H.L. (2009) Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease. Mol. Th. J. Am. Soc. Gene Ther., 17, 1563-1573.
40. LaFerla, F.M. and Oddo, S. (2005) Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol. Med., 11, 170-176.
41. Piedrahita, D., Hernandez, I., Lopez-Tobon, A., Fedorov, D., Obara, B., Manjunath, B.S., Boudreau, R.L., Davidson, B., Laferla, F., Gallego-Gomez, J.C. et al. (2010) Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice. J. Neurosci., 30, 13966-13976.
42. Brunden, K.R., Trojanowski, J.Q. and Lee, V.M. (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat. Rev. Drug Discov., 8, 783-793.
43. Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., Gerstein, H., Yu, G.Q. and Mucke, L. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science, 316, 750-754.
44. Roberson, E.D., Halabisky, B., Yoo, J.W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.Q. et al. (2011) Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci., 31, 700-711.
45. Halliday, G.M. and McCann, H. (2010) The progression of pathology in Parkinson's disease. Ann. N Y Acad. Sci., 1184, 188-195.
46. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
47. Hardy, J. (2010) Genetic analysis of pathways to Parkinson disease. Neuron, 68, 201-206.
48. Sapru, M.K., Yates, J.W., Hogan, S., Jiang, L., Halter, J. and Bohn, M.C. (2006) Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol., 198, 382-390.
49. Fountaine, T.M. and Wade-Martins, R. (2007) RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J. Neurosci. Res., 85, 351-363.
50. Liu, D.M., Jin, L., Wang, H., Zhao, H.Y., Zhao, C.L. and Yang, H. (2008) RNA interference mediated silencing of alpha-synuclein in MN9D cells and its effects on cell viability. Neurosci. Bull., 24, 96-104.
51. Gorbatyuk, O.S., Li, S., Nash, K., Gorbatyuk, M., Lewin, A.S., Sullivan, L.F., Mandel, R.J., Chen, W., Meyers, C., Manfredsson, F.P. et al. (2010) In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol. Ther., 18, 1450-1457.
52. Ross, C.A. and Tabrizi, S.J. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol., 10, 83-98.
53. Durr, A. (2010) Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol., 9, 885-894.
54. Finsterer, J. (2010) Perspectives of Kennedy's disease. J. Neurol. Sci., 298, 1-10.
55. Yamada, M., Shimohata, M., Sato, T., Tsuji, S. and Takahashi, H. (2006) Polyglutamine disease: recent advances in the neuropathology of dentatorubral-pallidoluysian atrophy. Neuropathology, 26, 346-351.
56. Scholefield, J. and Wood, M.J. (2010) Therapeutic gene silencing strategies for polyglutamine disorders. Trends Genet., 26, 29-38.
57. Boudreau, R.L. and Davidson, B.L. (2010) RNAi therapeutics for CNS disorders. Brain Res., 1338, 112-121.
58. Xia, H., Mao, Q., Eliason, S.L., Harper, S.Q., Martins, I.H., Orr, H.T., Paulson, H.L., Yang, L., Kotin, R.M. and Davidson, B.L. (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a mouse model of SCA1. Nat. Med., 10, 816-820.
59. Harper, S.Q., Staber, P.D., He, X., Eliason, S.L., Martins, I., Mao, Q., Yang, L., Kotin, R.M., Paulson, H.L. and Davidson, B.L. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl Acad. Sci. USA, 102, 5820-5825.
60. Rodriguez-Lebron, E., Denovan-Wright, E.M., Nash, K., Lewin, A.S. and Mandel, R.J. (2005) Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther., 12, 618-633.
61. Wang, Y.L., Liu, W., Wada, E., Murata, M., Wada, K. and Kanazawa, I. (2005) Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci. Res., 53, 241-249.
62. DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R.K., Rajeev, K.G. et al. (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl Acad. Sci. USA, 104, 17204-17209.
63. Franich, N.R., Fitzsimons, H.L., Fong, D.M., Klugmann, M., During, M.J. and Young, D. (2008) AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol. Ther., 16, 947-956.
64. Boudreau, R.L., McBride, J.L., Martins, I., Shen, S., Xing, Y., Carter, B.J. and Davidson, B.L. (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther., 17, 1053-1063.
65. Drouet, V., Perrin, V., Hassig, R., Dufour, N., Auregan, G., Alves, S., Bonvento, G., Brouillet, E., Luthi-Carter, R., Hantraye, P. et al. (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol., 65, 276-285.
66. Duyao, M.P., Auerbach, A.B., Ryan, A., Persichetti, F., Barnes, G.T., McNeil, S.M., Ge, P., Vonsattel, J.P., Gusella, J.F., Joyner, A.L. et al. (1995) Inactivation of the mouse Huntington's disease gene homolog Hdh. Science., 269, 407-410.
67. Nasir, J., Floresco, S.B., O'Kusky, J.R., Diewert, V.M., Richman, J.M., Zeisler, J., Borowski, A., Marth, J.D., Phillips, A.G. and Hayden, M.R. (1995) Targeted disruption of the Huntington's disease gene resultsin embryonic lethality and behavioral and morphological changes in heterozygotes. Cell, 81, 811-823.
68. Dragatsis, I., Levine, M.S. and Zeitlin, S. (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet., 26, 300-306.
69. Alves, S., Nascimento-Ferreira, I., Auregan, G., Hassig, R., Dufour, N., Brouillet, E., Pedroso de Lima, M.C., Hantraye, P., Pereira de Almeida, L. and Deglon, N. (2008) Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS ONE, 3, e3341.
70. Scholefield, J., Greenberg, L.J., Weinberg, M.S., Arbuthnot, P.B., Abdelgany, A. and Wood, M.J. (2009) Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS ONE, 4, e7232.
71. Pfister, E.L., Kennington, L., Straubhaar, J., Wagh, S., Liu, W., DiFiglia, M., Landwehrmeyer, B., Vonsattel, J.P., Zamore, P.D. and Aronin, N. (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol., 19, 774-778.
72. Lombardi, M.S., Jaspers, L., Spronkmans, C., Gellera, C., Taroni, F., Di Maria, E., Donato, S.D. and Kaemmerer, W.F. (2009) A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol., 217, 312-319.
73. Hu, J., Liu, J. and Corey, D.R. (2010) Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem. Biol., 17, 1183-1188.
74. Watase, K., Barrett, C.F., Miyazaki, T., Ishiguro, T., Ishikawa, K., Hu, Y., Unno, T., Sun, Y., Kasai, S., Watanabe, M. et al. (2008) Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant CaV2.1 channels. Proc. Natl Acad. Sci. USA, 105, 11987-11992.
75. Fonseca, S.B., Pereira, M.P. and Kelley, S.O. (2009) Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev., 61, 953-964.
76. Bonoiu, A.C., Mahajan, S.D., Ding, H., Roy, I., Yong, K.T., Kumar, R., Hu, R., Bergey, E.J., Schwartz, S.A. and Prasad, P.N. (2009) Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc. Natl Acad. Sci. USA, 106, 5546-5550.
77. Cardoso, A.L., Simoes, S., de Almeida, L.P., Plesnila, N., Pedroso de Lima, M.C., Wagner, E. and Culmsee, C. (2008) Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS. J. Control Release, 132, 113-123.
78. Pulford, B., Reim, N., Bell, A., Veatch, J., Forster, G., Bender, H., Meyerett, C., Hafeman, S., Michel, B., Johnson, T. et al.. (2010) Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS ONE, 5, e11085.
79. Uno, Y., Piao, W., Miyata, K., Nishina, K., Mizusawa, H. and Yokota, T. (2010) HDL facilitates in vivo delivery of -tocopherol-conjugated siRNA to the brain. Hum. Gene Ther. [Epub ahead of print].
80. Kumar, P., Wu, H., McBride, J.L., Jung, K.E., Kim, M.H., Davidson, B.L., Lee, S.K., Shankar, P. and Manjunath, N. (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature, 448, 39-43.
81. Robbins, M., Judge, A. and MacLachlan, I. (2009) siRNA and innate immunity. Oligonucleotides, 19, 89-102.
82. Iguchi, H., Kosaka, N. and Ochiya, T. (2010) Secretory microRNAs as a versatile communication tool. Commun. Integr. Biol., 3, 478-481.
83. Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J.J. and Lotvall, J.O. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol., 9, 654-659.
84. Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, J., Guo, X. et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res., 18, 997-1006.
85. Kosaka, N., Iguchi, H., Yoshioka, Y., Takeshita, F., Matsuki, Y. and Ochiya, T. (2010) Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem., 285, 17442-17452.
86. Pegtel, D.M., Cosmopoulos, K., Thorley-Lawson, D.A., van Eijndhoven, M.A., Hopmans, E.S., Lindenberg, J.L., de Gruijl, T.D., Wurdinger, T. and Middeldorp, J.M. (2010) Functional delivery of viral miRNAs via exosomes. Proc. Natl Acad. Sci. USA, 107, 6328-6333.
87. Wang, K., Zhang, S., Weber, J., Baxter, D. and Galas, D.J. (2010) Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res., 38, 7248-7259.
88. Hong, H., Zhang, Y. and Cai, W. (2010) In vivo imaging of RNA interference. J. Nucl. Med., 51, 169-172.